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SUMMARY
Late potentials (LP) detected on the signal-averaged electrocardiogram (SAECG) pre-
dict arrhythmic events after acute myocardial infarction (AMI). It is also well established
that successful thrombolytic therapy reduces the incidence of LP. Our aim was to evaluate
the effects of a beta-blocker on LP in patients receiving thrombolytic therapy. We studied
40 patients presenting with anteroseptal AMI (< 6 hours). All patients received throm-
bolytic therapy and were evaluated with coronary angiography at predischarge. Eighteen
patients received metoprolol (5 mg IV on admission followed by 50 mg BID). SAECG
recordings were obtained serially using an ART system (40-250 Hz filter, noise < 0.5 mV)
prior to thrombolytic therapy, after 48 hours and after 10 days. LP was defined as posi-
tive if the SAECG met at least 2 of the Gomes criteria. Changes observed in SAECG
recordings after thrombolytic therapy were correlated with angiographic and clinical data
with regard to the usage of BB. The frequencies of LP before and after thrombolytic ther-
apy were compared with the McNemar test. There were no significant differences
between the clinical characteristics, risk factors, and angiographic findings (including inf-
arct related artery patency and LV functions) of the groups. Baseline SAECG findings
were also similar between the groups. The incidence of LP significantly decreased after
TT in the BB group, however, this change was not observed in patients who did not
receive BB (P = 0.012, McNemar test). Beta-blockers reduce the incidence of LPs fol-
lowing thrombolytic therapy in patients with anterior AMI. This might be explained by
the possible beneficial effect of BB on the arrhythmogenic substrate.  (Jpn Heart J 2004;   
45: 11-21)
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MOST sudden cardiac deaths are caused by fatal ventricular arrhythmias pre-
cipitated by early myocardial ischemia of acute myocardial infarction (AMI).
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Electrical signals with high frequency and low amplitude following the QRS
complex are termed ventricular late potentials (VLPs) and when detected on a
signal-averaged electrocardiogram (SAECG) predict spontaneous or inducible
ventricular arrhythmias or sudden death after AMI.1) VLPs have been more fre-
quently documented in AMI with reduced ejection fraction (EF%) and their prog-
nostic significance is independent of the EF% itself.2-5) These VLPs have been
recorded in 70 to 90% of patients with sustained and inducible ventricular tachy-
cardia after myocardial infarction, in only 0 to 6% of normal volunteers, and in 7
to 15% of patients after myocardial infarction that do not have ventricular tachy-
cardia.6) Early administration of beta-blockers (BB) and thrombolytic agents has
shown beneficial effects on both short and long-term prognoses in AMI.7) BB
treatment is frequently used in AMI for its cardioprotective, antiarrhythmic, anti-
anginal and antihypertensive effects. The mode of action, however, is not known.
It is also well established that BB reduce the incidence of sudden deaths.8-10)
Therefore, treatment strategies that reduce the VLP incidence at the same time
could reduce mortality in AMI. Until now several studies have suggested that
treatments decreasing the frequency of late potentials following AMI may
improve prognosis.11,12) This study was designed to test the hypothesis whether
BB treatment has possible beneficial effects on the arrhythmogenic substrate.
METHODS
Patients and study protocol: This clinical study initially included 63 consecutive
patients with acute anterior myocardial infarction who were admitted to a coro-
nary care unit within 6 hours after symptom onset. All patients received throm-
bolytic therapy (tissue plasminogen activator, 100 mg accelerated regimen) and
were evaluated with coronary angiography at predischarge. Nitrates and aspirin
administration were started in the emergency room just before the initiation of
thrombolytic therapy. Heparin was first given as a 5000 U intravenous bolus and
then coadministered with the thrombolytic therapy. ACE inhibitors were given
upon the initiation of thrombolytic therapy. SAECG recordings were obtained
serially before, 48 hours after, and 10 days after reperfusion therapy.
The diagnosis of AMI was established by the presence of at least 2 of the
following WHO criteria: typical chest pain at least 30 minutes in duration, typical
ST segment elevation (in at least 2 consecutive precordial leads > 0.2 mV), and
elevation of serum creatine phosphokinase levels to at least twice the upper limit
of normal. The success of reperfusion therapy was defined as positive if at least 2
of the following reperfusion criteria were met: 1) ST segment resolution of
≥ 50%, 2) appearance of reperfusion arrhythymias, or 3) resolution of chest pain
within 90 minutes. Exclusion criteria were: (1) contraindications for thrombolytic
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therapy, (2) age > 75 years, (3) history of myocardial infarction, (4) history of
previous revascularization procedures, (5) presence of intraventricular conduc-
tion delay (QRS ≥ 120 ms), bundle branch block, atrioventricular block, atrial
fibrillation or pacemaker dependency, (6) ejection fraction < 40% on echocardio-
graphy (for excluding the effect of reduced ejection fraction on VLPs), (7) pres-
ence of a noise level > 0.5 µV in the composite lead of the SAECG, (8) presence
of clinical failure of reperfusion, (9) presence of nonpatent infarct-related arteries
on coronary angiogram, (10) presence of previous beta-blocker treatment, (11)
presence of continuous antiarrhythmic treatment before and after an in-hospital
period, and (12) patients with heart failure (Killip class ≥ 2). Three patients who
died due to cardiogenic shock during the reperfusion therapy, eight who refused
to undergo coronary angiography, two with nonpatent infarct related arteries on
coronary angiogram, nine with an ejection fraction < 40%, and one with normal
coronaries were excluded. Therefore, the study group consisted of 40 patients.
Careful continuous arrhythmia monitoring was performed by a cardiologist or
trained nurses for at least 3 days in a coronary care unit, and by telemetric moni-
torization (Space Lab, Inc) until discharge. Life-threatening ventricular tach-
yarrhythmia was defined as ventricular fibrillation or sustained ventricular
tachycardia. Changes observed in SAECG recordings after thrombolytic therapy
were correlated with angiographic and clinical data with regard to the usage of
beta-blocker treatment. Informed consent was obtained from all participants. The
local ethics committee approved the study protocol. All patients received intrave-
nous nitrates and heparin infusions (≤ 2 days) and angiotensin converting enzyme
inhibitor treatment on the first day of hospitalisation.
Beta-blocker treatment protocol: Metoprolol was given as a beta-blocker. Pa-
tients with heart failure (Killip class ≥ 2, these patients were also excluded from
the study), hypotension (BP < 90 mm Hg), bradycardia (heart rate < 60 bpm), or
heart block (PR > 0.24 sec) were excluded and thus not given BB treatment.13)
Metoprolol was given as 5 mg intravenous boluses three times on admission.
Patients were observed for 2 to 5 minutes after each bolus and if the heart rate fell
below 60 beats/min or systolic blood pressure decreased below 100 mmHg, no
further drug was given; a total of three intravenous doses (15 mg) was adminis-
tered. If hemodynamic stability continued, 15 minutes after the last intravenous
dose, the patients were started on oral metoprolol, 50 mg every 6 hours for 2 days,
and then switched to 100 mg twice daily. A total of 18 patients tolerated the BB
after the first administration of a low dose (group I), and 22 did not tolerate the
BB after the first administration (group II).
Angiographic evaluation: Routine coronary angiography was performed 8 ± 4
days after acute anterior myocardial infarction. The severity of coronary artery
stenosis was assessed and classified according to the American Heart Association
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system.14) The percent stenosis of a coronary artery was determined by a hand-
held caliper measurement. Significant angiographic coronary stenosis was
defined as the presence of stenosis > 70% of the luminal diameter. Multivessel
disease was defined as the presence of significant stenosis in more than 1 of the 3
major epicardial coronary arteries. The presence of stenosis in the left main cor-
onary artery with > 50% luminal diameter was also considered to be multivessel
disease. Left ventricular ejection fraction was measured angiographically at the
right anterior oblique view according to the area-length method. The perfusion
status of the infarct-related vessel was determined according to the Thrombolysis
In Myocardial Infarction (TINI) trial classification (coronary patency being
defined by a grade > 2).15) An experienced observer who was blinded to the
patient's history and SAECG findings interpreted the angiographic data.
Signal-averaged electrocardiography: The SAECGs were obtained 3 times in all
participating patients. SAECG recordings were performed prior to, 48 hours
after, and 10 days after thrombolytic therapy. Time domain signal-averaged
recordings were performed using Arrhythmia Research Technology (ART) model
1200 EPX (Austin, Texas) equipment. This system constituted a vector magni-
tude with a bidirectional bandpass filter system between 40 and 250 Hz combined
with standard bipolar orthogonal (X,Y, Z) leads. Signal averaging of > 300 beats
was performed to obtain a diastolic noise level of < 0.5 µV. The onset and offset
of the QRS complex were determined by an algorithm that calculated the total
QRS duration (QRSd), the root mean square voltage of the last 40 ms (RMS 40)
of the QRS complex, and the duration of the terminal low (< 40 µV) amplitude
signals (LAS 40) of the QRS complex. The late potentials were defined to be
present if the SAECG met 2 of the following criteria: filtered QRSd > 114 ms,
RMS 40 < 20 µV, or LAS 40 > 38 ms.16)
Echocardiographic examination: Echocardiographic examinations were per-
formed to detect patients having a left ventricular EF > 40% in the early period.
At a mean of day 2 (range, 1-3), patients underwent echocardiographic evaluation
using a Hewlett Packert Sonos 2500 system equipped with a 2.5 MHz transducer.
Parasternal long axis and apical four chamber views were assessed according to
the recommendations of American Society of Echocardiography.17) EF was calcu-
lated using a modified Simpson formula.
Statistical analysis: Data are expressed as proportions or the mean ± SD, with
statistical significance set at the 0.05 level. Students t test was used for the evalu-
ation of continuous variables in the 2 groups. Chi-square analysis and Student's
unpaired t test were used to compare variables between groups for univariate
analysis. The paired Studen's t test was performed to compare SAECG variables
before and after thrombolytic therapy. Changes in the frequency of late potentials
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were compared with the McNemar test according to the presence of beta-blocker
treatment.
RESULTS
The β-blocker (BB) metoprolol was administered to 18 (45%) patients. As
summarized in Table I, there were no significant differences between those with
and without BB in terms of clinical characteristics, including coronary risk fac-
tors, angiographic findings (including infarct related artery patency and left ven-
tricular function), and previous medications. Clinical variables related to the
reperfusion therapy were also similar in the two groups.
The SAECG findings are listed in Table II. There was no overall difference
between the baseline SAECG parameters of the groups. After thrombolytic ther-







Age (yr, mean ± SD)
Gender (female/male)
Cardiac risk factors, n (%)
    Family history of CAD
    Hypertension
    Diabetes mellitus
    Cigarette smoking
    Lipidemia
    Obesity (BMI >30 kg/m2) 
Time from chest pain to thrombolysis
 (min, mean ± SD) 
IRA % diameter stenosis (mean ± SD)
IRA, n (%)
     LAD 
One vessel disease, n (%) 
Multivessel disease, n (%)
Echocardiographic LVEF (%, mean ± SD)
Ventricular arrhythmias during in-hospital 
period, n (%)
Medication before infarction
    Aspirin
    Ca antagonists
    Beta-blockers
    Anti-arrhythmics































































BMI = body mass index; CAD = coronary artery disease; IRA = infarct related artery, LAD = left anterior descend-
ing artery; LVEF = left ventricular ejection fraction; ACEI; angiotensin converting enzyme inhibitors, SD = stan-
dard deviation; NS = not significant.
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apy, both the 48th hour values of total QRS and LAS, and the 10th day values of
LAS and RMS were significantly better in the BB group patients. After thrombo-
lysis, the total QRS duration and RMS 40 values changed significantly at the 10th
day SAECG recording in group I (total QRS: 115 ± 32 ms versus 90 ± 10 ms after
the treatment [P = 0.02]; RMS 40: 41 ± 9 µV versus 58 ± 7 µV after the treatment
[P = 0.03]). The group II patients did not show any significant changes in quanti-
tative SAECG parameters after reperfusion therapy.
The effect of successful thrombolysis on the incidence of late potentials is
shown in Figure 1. The incidence of late potentials was not statistically different
between the groups (22% vs 23%, P > 0.05) at baseline recordings of SAECG,
however, in the 10th day recordings the incidence of late potentials was less fre-
quent in the BB group than in group II (Figure 1). In group I, 4 patients (22%) had
late potentials at baseline before the thrombolytic therapy and both of these
patients had lost them by the 10th day, while 14 late potential negative patients had
no change, and none had a change from normal to abnormal (Figure 2). These
changes in group I were statistically significant (P = 0.012, McNemar test). In
group II, the prethrombolytic late potentials were positive in 5 (23%) patients
who remained positive on the 10th day also, but 1 changed from normal to abnor-
mal and 16 late potential negative patients had not changed 10 days later. These
changes were not statistically significant (P > 0.05, McNemar test). Patients in
group I also experienced less frequent life-threatening ventricular arrhythmias
during the in-hospital period although the difference between the groups was not
Table II. SAECG Parameters
Group I (n = 18)
with beta-blocker
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      Baseline
      48th hour
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RMS 40 (µV)
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All data are expressed as the mean ± SD. LAS 40 = low amplitude sig-
nals < 40 µV; QRSd = QRS duration; RMS 40 = root-mean square volt-
age of terminal 40 ms of QRS complex.
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statistically significant [6 (33%) patients in group I vs 10 (46%) patients in group
II, P > 0.05)].
DISCUSSION
Electrical signals with high frequency and low amplitude following the QRS
complex are termed ventricular late potentials and are detected on signal-aver-
aged electrocardiograms (SAECG). Ventricular late potentials result from the
Figure 2. The change in late potential incidences in patients treated with and without the beta-blocker
metroprolol.
Figure 1. The incidence of late potentials decreased significantly after thrombolytic therapy in patients with beta-blocker
treatment, however, this change was not observed in patients without beta-blocker treatment.
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slowed down electrical transmission across the damaged myocardial area.18-21)
The presence of VLPs constitutes an anatomical substrate for repeated ventricular
arrhythmia.22) Late potentials can be detected as early as 3 hours after the onset of
the chest pain and increase in prevalence in the first week of infarction. Early use
of thrombolytic agents may reduce the prevalence of the late potentials after cor-
onary occlusion.6) Ventricular tachycardia and fibrillation are considered to be the
most important mechanisms leading to sudden death following AMI. Therefore,
interventions to decrease the frequency of VLPs may provide a valuable contri-
bution to the prognosis.12,20)
Several studies have suggested that BB reduce the incidence of overall death
and sudden cardiac death after myocardial infarction.23-25) The mechanism of this
reduction in mortality is not entirely clear and may be related to a reduction in the
extent of ischemic drainage, autonomic effects, a direct antiarrhythmic effect,
reduction in VLP incidence, or a combination of these factors. Despite the well
known clinical importance of VLP and BB, the effects of BB on VLP are not
clear, although a few studies have suggested that treatment decreases the fre-
quency of late potentials following AMI.11) Determination of the effects of beta-
blockers on VLP may help in decisions regarding antiarrhythmic treatment fol-
lowing AMI and to determine the mechanisms of the drugs.
In this study, we attempted to evaluate the protective effect of beta-blocker
treatment on ventricular arrhythmias, by observing the changes in late potentials
during successful thrombolysis. There were no significant differences between
patients with and without BB treatment with regard to previous medication, left
ventricular ejection fraction, and concomitant medication during the hospitaliza-
tion period. None of the patients had received parenteral anti-ischemic therapy
before AMI. Therefore, the changes that we observed in late potentials after suc-
cessful thrombolysis in patients with BB cannot be the result of previous medica-
tion. In our study, we found that the use of BB leads to a significant decrease in
the frequency of VLP. Our result was similar to that of Santarelli, et al who
reported in the LAPIS (Late Potential Italian Study) multicenter trial that VLPs
were less frequently found in patients treated than in those not treated with beta-
blockers during hospitalization (15 vs 27%; P = 0.007); however, this effect was
found only in those with an ejection fraction greater than or equal to 40%.26) San-
tarelli, et al also found that independent predictors of VLPs by multivariate anal-
ysis were an ejection fraction < 40%, ventricular fibrillation in the acute phase,
and absence of beta-blocking therapy even though the patients receiving BB were
younger, had lower peak values of creatine kinase, and more frequently received
thrombolysis than those who did not receive BB in their study. However, there
were no significant differences between the clinical characteristics, risk factors,
and angiographic findings (including infarct related artery patency and LV func-
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tions) in our patient groups. So, the observed differences in VLP incidence
between the groups may be related to the β-blockade in our study, but may also
be due to the difference in hemodynamic response. Left ventricular ejection frac-
tion and life-threatening ventricular arrhythmias in the early phase of AMI were
not different between the two groups in our study.
To the best of our knowledge, this study is the first to investigate the serial
changes observed in SAECG parameters during successful thrombolysis in
patients who tolerate and do not tolerate β-blockade. In group I, the mean QRS
duration and RMS 40 values changed significantly at the 10th day evaluation
(Table II) after thrombolysis. But patients without BB did not show any signifi-
cant changes in any of the quantitative SAECG parameters after reperfusion.
Also, both the late potential positive patients in the BB group before thrombolysis
lost them, while there were no changes in the incidence of late potentials after
thrombolytic therapy in group II patients. Therefore, our results are slightly dif-
ferent from other trials in the literature. In our study, we found that the use of
thrombolytic treatment without BB did not lead to a decrease in the frequency of
VLP. However, Tobe, et al suggested that thrombolytic treatment only (streptoki-
nase, 1.5 million units) lead to a significant decrease in the frequency of VLP in
the first month after AMI compared to the nonstreptokinase group.27) They did
not separate the patients with respect to clinical variables (AMI localization, LV
function, infarct related artery patency, and medication). We believe that this dif-
ference can be explained by our relatively earlier SAECG recording time and
because we included patients only with patent infarct related arteries, EF > 40%,
and anterior AMI. Beauregard, et al found the high frequency QRS duration was
significantly shortened and an increase in RMS 40 voltage in patients with and
without BB after thrombolytic therapy.28) They also found that the prevalence of
VLP was higher in patients with Q wave infarctions or with occluded infarct
related arteries. Thus, they reported that these changes in myocardial activation
might be related to ischemia and reperfusion. Their study did not exclude patients
with nonpatent infarct related arteries, an ejection fraction < 40%, or non-Q
waves AMI, while our study was consisted of more homogenous groups and
excluded patients with nonpatent infarct related arteries. Therefore, the change in
VLP incidence may not be correlated with ischemia and may be related to
arrhythmogenic substrates that originated from infarcted regions in our study.
The major limitation of this study is the small sample size. However, the
study population was very homogeneous. Additionally, our limited number of
patients and very short duration of cardiac monitoring were not sufficient to
determine mortality or the anti-arrhythmic effect of metoprolol. However,
patients in group I also experienced less frequent life-threatening ventricular
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arrhythmias during the in-hospital period, although the difference between the
groups was not statistically significant (Table I).
Conclusion: In conclusion, our results suggest that beta-blocker treatment
reduces the incidence of late potentials following successful thrombolytic therapy
in AMI. The arrhythmogenic substrate in the infarcted region of the ventricular
myocardium and VLPs that originated from the infarcted region are electrophys-
iological indicators of arrhythmogenic substrate. This might be explained by the
possible beneficial effect of beta-blockers on the arrhythmogenic substrate in the
left ventricle. Further studies in a larger number of patients and long-term cardiac
monitorization are needed to support the opinion that the effect of BB on sudden
death in post-AMI patients is via a reduction in VLPs.
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